Vaccines are medicines that stimulate the immune system of the body to protect against foreign substances. The stimulated immune system destroys foreign bodies and remembers it. Vaccines work on this principle of memorizing foreign particle and prevent infection likely to be caused by this foreign particle when it invades again. Cancer vaccines are medicines categorized as biological response modifiers. These modifiers work by stimulating the immune system to fight against disease. Broadly, cancer vaccines are of two types: prevention vaccines and treatment vaccines. Preventive vaccines are used in healthy people to prevent cancer. Treatment vaccines are used in cancer patients to strengthen their natural immune response to fight the disease. Treatment vaccine is a type of immunotherapy. Preventive vaccines are available in the U.S. for human papillomavirus (HPV) and hepatitis B virus. Treatment vaccine is available for metastatic prostate cancer. Cancer preventive vaccines are more like traditional vaccines that recognize the foreign particle and strengthen the immune system against it. Preventive vaccines function by targeting viruses including those producing cancer and activate the immune system against those viruses by producing antibodies. Furthermore, cancer treatment vaccines boost body’s natural immune system to fight against cancer cells. Cancer treatment vaccines are provided to destroy cancer cells left in the body following other treatments, stop further spreading of cancer, and prevent cancer from recurring. Cancer vaccines can be administered intravenously in children as well as adults.
The World Health Organization reported around 14 million cases of cancer and 8.2 million cancer deaths in 2012. The most common forms among these were lung, colorectal, prostate, cervical, and breast cancers. Hence, demand for vaccines to prevent and treat cancers is high.
Many clinical trials are undergoing by NCI- supported cancer prevention or treatment for different types of cancer using vaccines. Increasing cancer patients, technological advancements, drug development in the field of cancer, government support, rising geriatric population, increasing health care services and expenditure, rising awareness in the incidences of cancer, and available therapies are the factors driving the cancer vaccines market. Low availability of cancer vaccines in remote areas and the need of cold storage and transportation are the factors hampering the growth of the cancer vaccines market.
The global cancer vaccines market has been segmented based on type of vaccine, application of vaccine, end-user, and region. In terms of type of vaccine, the market has been categorized into antigen vaccines, anti-idiotype vaccines, dendritic cell vaccines, whole cell vaccines, and DNA vaccines. Based on application of vaccines, the market has been segmented into preventive (or prophylactic) vaccines and treatment vaccines. Preventive vaccines approved in the U.S. are HPV and hepatitis B vaccines. Treatment vaccines can be of two types: autologous cancer vaccines (derived from oneself) and allogenic cancer vaccines (made from non-cancer cells of one’s own body). In terms of end-user, the cancer vaccines market has been divided into adults and children.
Geographically, the cancer vaccines market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the market owing to major market share of the U.S. However, the market in Asia Pacific is expected to expand at the highest CAGR during the forecast period due to rising government initiatives, increased focus of players on the vaccine technology market in India, and rising immunization initiatives by the World Health Organization and GAVI.
The global cancer vaccines market is dominated by key players such as AstraZeneca plc, Prima Sanofi, BioMed, GlaxoSmithKline, Merck, Aduro BioTech, OncoThyreon, and Oxford BioMedica.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.